Therapeutic and research application of PDCL3
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Aug 9, 2022
Grant Date -
Sep 28, 2017
app pub date -
Sep 15, 2015
filing date -
Sep 15, 2014
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
Described herein are novel compositions comprising, for example, PDCL3 polypeptides having VEGFR-2 inhibitory activity, inhibitory PDCL3 antibodies and PDCL3-binding fragments thereof, or PDCL3 inhibitory nucleic acid molecules, and methods of their use in anti-angiogenesis and anti-tumor proliferation and invasiveness therapies, such as the treatment of cancer, as well as the treatment of those vascular diseases where pathological angiogenesis plays a role, such as in carotid artery disease, macular degeneration, and plaque neovascularization. Also described herein are novel compositions comprising engineered PDCL3 polypeptides having enhanced chaperone activity, recombinant cells comprising such engineered PDCL3 polypeptides having enhanced chaperone activity, and methods thereof for therapeutic protein production and in vitro protein synthesis.
First Claim
Other Claims data not available
Family
International Classification(s)
- 2015 Application Filing Year
- A61K Class
- 16157 Applications Filed
- 11882 Patents Issued To-Date
- 73.55 % Issued To-Date
Cited Art Landscape
Patent Citation Ranking
- 0 Citation Count
- A61K Class
- 0 % this patent is cited more than
- 3 Age
Maintenance Fees
| Fee | Large entity fee | small entity fee | micro entity fee | due date |
|---|---|---|---|---|
| 3.5 Year Payment | $1600.00 | $800.00 | $400.00 | Feb 9, 2026 |
| 7.5 Year Payment | $3600.00 | $1800.00 | $900.00 | Feb 9, 2030 |
| 11.5 Year Payment | $7400.00 | $3700.00 | $1850.00 | Feb 9, 2034 |
